Table 1.

Descriptive statistics of patients providing tumor for models

Engraftment still under assessment (censored)EngraftedFailed engraftmentAllP value (engrafted vs. failed)
Patient age at collection, y median (range)62 (39–89)64 (29–91)62 (22–85)63 (22–91)0.77
Time (h) from FSL* to mouse, median (range)1.7 (1.1–2.8)1.7 (0.9–3.6)1.8 (0.9–7.3)1.7 (0.9–7.3)0.85
Morphology
 Serous15 (63%)111 (66%)24 (53%)150 (64%)0.018
 Mucinous2 (8%)2 (1%)2 (4%)6 (3%)
 Endometrioid1 (4%)11 (7%)6 (13%)18 (8%)
 Clear cell1 (4%)10 (6%)1 (2%)12 (5%)
 Mixed3 (13%)23 (14%)4 (9%)30 (13%)
 Undifferentiated01 (1%)1 (2%)2 (1%)
 Brenner001 (2%)1 (<1%)
 Carcinosarcoma06 (4%)2 (4%)8 (3%)
 Other2 (8%)3 (2%)4 (9%)7 (3%)
Timing of surgery
 Primary19 (73%)145 (86%)37 (82%)201 (84%)0.31
 Interval debulking0 (0%)4 (2%)0 (0%)4 (2%)
 Recurrent7 (27%)19 (11%)8 (18%)34 (14%)
Stage
 I—II4 (21%)35 (24%)15 (41%)54 (27%)0.049
 III—IV15 (79%)109 (76%)22 (59%)146 (73%)
Tumor grade
 Borderline1 (6%)1 (1%)4 (11%)6 (3%)0.00087
 Low4 (22%)14 (10%)7 (20%)25 (13%)
 High13 (72%)119 (89%)24 (69%)156 (83%)
Ascites
 Present8 (44%)77 (58%)9 (26%)94 (51%)0.00091
 Absent10 (56%)55 (42%)25 (74%)90 (49%)
  • *FSL, frozen section lab, which is the primary point of surgical material procurement.